Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 12Expanded_access 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Recurrence 1

Interventions

3-Iodobenzylguanidine 3talquetamab 2ibrutinib 2zanubrutinib 1vorasidenib 1sugemalimab 1revumenib 1pomalidomide 1loncastuximab tesirine 1fludarabine phosphate 1fludarabine 1denileukin diftitox 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1Whole-Body Irradiation 1Tacrolimus 1Panobinostat 1Mycophenolic Acid 1Immunotherapy, Adoptive 1Cytarabine 1Cyclophosphamide 1Cord Blood Stem Cell Transplantation 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Recurrence × zanubrutinib × Clear all
NCT04052854 2024-10-23

A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies

BeiGene

No longer available
Lymphoid

Waldenstrom Macroglobulinemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡